Lv72
4788 积分 2022-04-24 加入
First-Line Sacituzumab Govitecan Plus Pembrolizumab in Metastatic NSCLC: PD-L1 TPS Less Than 50% and More Than or Equal to 50% Cohorts of the EVOKE-02 Study
1小时前
已完结
Prognostic and predictive biomarkers in non-small cell lung carcinoma
6小时前
已完结
Sacituzumab Tirumotecan in Participants With Advanced or Metastatic Urothelial Carcinoma and Disease Progression after Chemotherapy and Immune Checkpoint Inhibitors
28天前
已完结
Sacituzumab Govitecan in Untreated, Advanced Triple-Negative Breast Cancer
29天前
已完结
Sacituzumab Govitecan in Untreated, Advanced Triple-Negative Breast Cancer
29天前
已完结
First-line sacituzumab tirumotecan with tagitanlimab in advanced non-small-cell lung cancer: a phase 2 trial
29天前
已完结
Sacituzumab Tirumotecan in EGFR-TKI–Resistant, EGFR -Mutated Advanced NSCLC
29天前
已完结
Sacituzumab Tirumotecan in EGFR-TKI–Resistant, EGFR -Mutated Advanced NSCLC
29天前
已完结
Sacituzumab Tirumotecan in EGFR-TKI–Resistant, EGFR -Mutated Advanced NSCLC
29天前
已完结
TROP-2-targeted antibody-drug conjugate SHR-A1921 for advanced or metastatic solid tumors: A first-in-human phase 1 study
1个月前
已完结
皖公网安备34019202002308
